Translational Lung Cancer Research

Papers
(The H4-Index of Translational Lung Cancer Research is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series71
Pushing the boundaries of minimally invasive surgery67
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer52
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report51
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer43
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors41
End-to-side anastomosis in complex tracheal resection and reconstruction: a case series study40
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–203031
Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females30
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report29
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer29
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer28
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)27
Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays27
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network25
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer25
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review25
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy25
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?24
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?24
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression23
Dynamic change of CD8+ T cell: immunotherapy fate tell?22
Real-world data on severe lung cancer: a multicenter retrospective study22
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions22
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma22
The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer22
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial22
0.033947944641113